| 货号 | 11126-100mg |
| 描述 | Suramin is a polysulfonated naphthylurea that inhibits the binding of calmodulin to recognition sites on the ryanodine receptor-1 (IC50 = 4.9 μM), blocks G protein coupling to GPCRs, and non-selectively antagonizes P2 purinergic receptors (10-100 μM).1,2 Suramin also acts as a non-specific competitor of glycosaminoglycan binding to a variety of targets including TGFβ, PDGF, and FGF and additionally inhibits insulin-like growth factor-l, EGF, PKC activity, TNF, IL-2, transferrin, and Apo-B.3 While originally used as an early stage treatment of trypanosome-caused onchocerciasis (African river blindness) and African trypanosomiasis (African sleeping sickness), suramin has been under clinical evaluation for its potential to regress a number of cancer cell lines, including non-small cell lung cancer, advanced breast cancer, hormone refractory prostate cancer, metastatic renal cell cancer, colorectal cancer, and high-grade gliomas.3,4,5 |
| 别名 | BAY 205;Germanin;NF 060; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Klinger, M.,Bofill-Cardona, E.,Mayer, B., et al. Suramin and the suramin analogue NF307 discriminate among calmodulin-binding sites. Biochemistry Journal 355(3), 827-833 (2001). 2.Charlton, S.J.,Brown, C.A.,Weisman, G.A., et al. PPADS and suramin as antagonists at cloned P2Y- and P2U- purinoceptors. British Journal of Pharmacology 118(3), 704-710 (1996). 3.Eisenberger, M.A. and Reyno, L.M. Suramin. Cancer Treatment Reviews 20, 259-273 (1994). 4.Stein, C.A. Suramin: A novel antineoplastic agent with multiple potential mechanisms of action. Cancer Research 53, 2239-2248 (1993). 5.McGeary, R.P.,Bennett, A.J.,Tran, Q.B., et al. Suramin: Clinical uses and structure-activity relationships. Mini Rev.Med.Chem. 8(13), 1384-1394 (2008). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | 22 |
| 纯度 | ≥98% |
| 计算分子量 | 1429.1 |
| 分子式 | C51H34N6O23S6 • 6Na |
| CAS号 | 129-46-4 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |